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Highlights 
• Irisin, the cleaved extra-cellular fragment of FNDC5 is a myokine thought to have favorable 
metabolic activity. 
• The role of variants in the FNDC5 gene in NAFLD is not defined. 
• Genetic variants in FNDC5 confer risk of human severe hepatic steatosis. 
• Functional studies reveal that this variant mediates this effect via a miRNA-mediated control of 
FNDC5 mRNA stability. 
• Irisin is likely to have a favourable metabolic impact on NAFLD. 
 Background & Aims 
Irisin, the cleaved extra-cellular fragment of the Fibronectin type III domain-containing protein 5 
(FNDC5) is a myokine that is proposed to have favorable metabolic activity. We aimed to elucidate 
the currently undefined role of variants in the FNDC5 gene in non-alcoholic fatty liver disease 
(NAFLD). Methods 
We prioritized single nucleotide polymorphisms in FNDC5 on the basis of their putative biological 
function and identified rs3480 in the 3′ untranslated region (3′UTR). We studied the association of 
rs3480 with liver disease severity and the metabolic profile of 987 Caucasian patients with NAFLD. 
Functional investigations were undertaken using luciferase reporter assays of the 3′UTR of human 
FNDC5, pyrosequencing for allele-specific expression of FNDC5 in liver, measurement of serum 
irisin, and bioinformatics analysis. Results 
The rs3480 (G) allele was associated with advanced steatosis (OR 1.29; 95% CI 1.08–1.55; 
p = 0.004), but not with other histological features. This effect was independent but additive to 
PNPLA3 and TM6SF2. The rs3480 polymorphism influenced FNDC5 mRNA stability and the 
binding of miR-135a-5P. Compared with controls, hepatic expression of this microRNA was 
upregulated while FNDC5 expression was downregulated. Elevated serum irisin was associated 
with reduced steatosis, and an improved metabolic profile. 
Conclusions 
Carriage of the FNDC5 rs3480 minor (G) allele is associated with more severe steatosis in NAFLD 
through a microRNA-mediated mechanism controlling FNDC5 mRNA stability. Irisin is likely to 
have a favorable metabolic impact on NAFLD. Lay summary 
Irisin is a novel protein produced mainly by muscle, which is known to be released into the 
circulation, with an unclear role in liver fat deposition. This study demonstrates that genetic variants 
in the gene encoding the irisin protein modulate the risk of liver fat in patients with fatty liver 
disease. Interestingly, these effects are independent of, but additive to those of other recently 
described genetic variants that contribute to liver fat. In functional studies, we have deciphered the 
detailed molecular mechanisms by which this genetic variant mediates its effects. Graphical abstract 
 
 
 
 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a principal liver disorder in Western countries and is 
on trajectory to become the leading cause of end-stage liver disease and liver transplantation.[1], 
[2], [3] Notably, NAFLD is part of a multisystem metabolic disturbance, as its impact is not limited 
to the liver but also affects extra-hepatic sites such as the cardiovascular system and kidneys.4 In 
NAFLD, there is pathological hepatic accumulation of fat that over time can lead to inflammation 
and progress to cirrhosis, end-stage liver disease and hepatocellular carcinoma. The mechanisms 
underlying the accumulation of liver fat are complex and gene × environment interactions play a 
critical role.[5], [6], [7] 
The heritable component of hepatic steatosis has been estimated at ∼50% based on a prospective 
twin study.8 To date, the major inherited determinants of hepatic fat accumulation based on genome 
wide association studies are the patatin-like phospholipase domain-containing 3 (PNPLA3) I148M 
and the transmembrane 6 superfamily member 2 (TM6SF2) E167K gene variants.[9], [10]. 
However, these polymorphisms explain only 10–20% of the heritability.[6], [11] Thus, other as yet 
unidentified genetic and epigenetic variations likely exist to explain the missing heritability. 
Adipose-derived hormones, collectively termed adipokines are established drivers/contributors to 
the pathogenesis of NAFLD.[12], [13], [14] More recently, the myokine irisin was isolated from 
muscle by Boström et al. 2012.15 Irisin is a 12 kD, 112 amino acid fragment that is proteolytically 
processed from the fibronectin type III domain-containing protein 5 (FNDC5) and released into the 
circulation.16 The functions of irisin and even its existence however have been a matter of 
debate,[16], [17] with some reports suggesting that the irisin polypeptide is a “myth”.17 Human 
FNDC5 has an atypical ATA translation start codon rather than the ATG sequence. Hence, it has 
been argued that the human ATA codon represents a null mutation without irisin production and 
that reports measuring human irisin are an artefact from using an FNDC5 antibody with poor 
specificity.17 However, recent work using quantitative mass spectrometry has confirmed the 
existence of circulating irisin.18 The 3 published reports have shown inconsistent associations of 
NAFLD with irisin levels;[19], [20], [21] in addition, the role of genetic variants in FNDC5 and the 
mechanisms involved have not been well defined. 
In this work, after single nucleotide polymorphism (SNP) prioritization, we explored the role of the 
FNDC5 polymorphism rs3480 on hepatic steatosis and other histological features in a cohort of 987 
Caucasian patients with NAFLD and investigated the mechanisms underlying the association. Patients and methods Patient cohort 
The study comprised 987 Caucasian patients with biopsy-proven NAFLD. The details of the cohort 
and their clinical and laboratory assessment are provided in the supplementary information. Ethics 
approval was obtained from the Human Research Ethics Committees of the Western Sydney Local 
Health District and the University of Sydney. All other sites had ethics approval from their 
respective ethics committees. Prioritization of FNDC5 SNPs 
To prioritize SNPs for genotyping, we followed the scheme illustrated in Fig. S1. In brief, common 
SNPs (minor allele frequency [MAF] >1%) within the FNDC5 gene were tested for their status as 
expression quantitative trait loci (eQTLs) using the GTEx (Genotype-Tissue Expression) project,22 
as well as eQTLs from the MuTHER study using the exSNP database.23 SNPs that were eQTLs for 
FNDC5 were then investigated for p values for the eQTL. Following this filter, 2 SNPs (rs3480 and 
rs10753269) in tight LD (r2 = 0.99) were found; the latter is upstream of FNDC5, while rs3480 is 
located in the 3′UTR. From this scheme, rs3480 was determined to be the SNP with the highest 
priority for genotyping in our cohort. Genotyping 
Genotyping for FNDC5 rs3480, PNPLA3 rs738409 and TM6SF2 rs58542926 was undertaken using 
the TaqMan SNP genotyping allelic discrimination method (Applied Biosystems, Foster City, CA, 
USA). All genotyping was blinded to clinical variables. Some of the PNPLA3 rs738409 and 
TM6SF2 rs58542926 genotyping data were extracted from a recent report.24 Liver histopathology 
Liver biopsies were scored by an expert liver pathologist in each participating center who was 
unaware of clinical or genetic data. Histological scoring was based on the system proposed by 
Kleiner et al.25 Steatosis was graded from 0 to 3, lobular inflammation from 0 to 3 and 
hepatocellular ballooning from 0 to 2. Fibrosis was staged from 0 to 4 with 4 representing cirrhosis. 
The NAFLD activity score (NAS) was calculated to quantify disease activity.25 The inter-observer 
agreement between pathologists was studied previously and was excellent for steatosis (κ = 0.85) 
and good for fibrosis (κ = 0.78).26 Allele-specific expression 
Allelic ratios quantified by pyrosequencing were performed at the Australian Genome Research 
Facility. Full details are provided in supplementary methods, Table S1 and Fig. 2. 
 
 Fig. 1. FNDC5 alleles association with the severity of hepatic steatosis. (A) Forest plot of associations of 
rs3480 with the severity of hepatic steatosis in individual samples and in the combined, fixed-effects meta-
analysis (n = 987). (B) Association between the number of PNPLA3, TM6SF2, and FNDC5 risk alleles and 
the severity of hepatic steatosis. The bar plots show the ORs (95% CI) for each number of risk alleles using 
zero risk alleles as the reference (right y axis). The histogram denotes the proportion of individuals in each 
genotype score category (left y axis). ORs, Odds ratios. 
 
 
Fig. 2. Allele-specific regulation of FNDC5 by miRNA-135a-5P. (A) FNDC5 dual luciferase reporter 
constructs. The 3′UTR of FNDC5 was cloned downstream of luciferase, which is driven by the constitutive 
Pgk promoter. (B) Stability of luciferase mRNA in Huh-7 cells transfected with the FNDC5-A or FNDC5-G 
luciferase construct and treated with actinomycin D (ActD) to arrest new transcription, presented as mRNA 
remaining over time relative to that at 0 h, set as 100%. Half-lives (50% mRNA remaining (dashed line)): 
FNDC5-A 3′UTR, 6.2 h; FNDC5-G 3′UTR, 3.7 h. (C) Bioinformatic analyses showing that rs3480 is the 
predicted target gene for miR-135a-5p and miR-135b-5p. (D) The miRNA mimics or miR inhibitor were co-
transfected with the reporter gene constructions into Huh-7 cells. Luciferase assay showing that miR-135a-
5p binds preferentially to the G allele, while there was less binding to the A allele. (E) Depletion of miR-
135a-5p by miR inhibitor abrogated the difference in luciferase activity between the 2 alleles. (F) Gene set 
enrichment analysis of pathways targeted by miR-135a-5p showing −log p value (Table S5). *p <0.05, 
**p <0.01, ***p <0.001 by 2-tailed Student’s t test. Error bars represent standard error of the mean. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Serum irisin level was measured using a recently released irisin kit from Phoenix Pharmaceuticals 
(EK-067-29)27 in a sub-cohort of 152 patients with available serum samples and with characteristics 
similar to the entire cohort. 
 Bioinformatics analyses 
We queried the online miRdSNP database which is based on TargetScan and PicTar databases28 to 
determine whether rs3480 (the SNP derived from our prioritization approach) in the 3′UTR of 
FNDC5 could be in miRNA target sites. Secondary structures of the mRNA and minimum folding 
energy (MFE) of FNDC-G and FNDC5-A were extrapolated using the RNAfold online server 
(Vienna RNA package, version 2.0.0, with option ‘-p’).29 
 Gene set enrichment analysis 
The target genes of MiR135a predicted by TargetScan. Gene set enrichment analysis used the 
Database for Annotation, Visualization and Integrated Discovery (DAVID)30 to ask which Kyoto 
Encyclopedia of Genes and Genomes (KEGG) were enriched within the genes that contained 
binding sites for miR-135a. Luciferase reporter assay 
The full-length 3′UTR of human FNDC5, with genetic variation corresponding to A or G (of 
rs3480) was cloned into the PmeI/SalI restriction site downstream of the gene encoding firefly 
luciferase in the pmirGLO reporter vector (Promega). Human liver sample miRNA extraction and Droplet Digital™ PCR 
RNA was extracted from 5 μm of liver tissue (obtained from resections and stored at −80 °C) using 
the miRNeasy kit (Qiagen) from 20 individuals (n = 10 controls and n = 10 with NAFLD). The first-
strand complementary synthesis reaction (cDNA) was performed using the TaqMan MicroRNA 
Reverse Transcription kit (Life Technologies) for miRNAs. 
For miRNAs and FNDC5 copy number quantification, droplet digital PCR was performed, as 
previously described.[31], [32] 
 Statistical methods 
Results are expressed as mean ± SD (standard deviation), median and interquartile range or number 
(percentage) of patients. All tests were 2-tailed and p values <0.05 were considered significant. 
For further details regarding the materials and methods used, please refer to the CTAT table and 
supplementary information. 
 Results 
FNDC5 rs3480 and the degree of hepatic steatosis 
Baseline characteristics of the cohort are summarized in Table S2. After SNP prioritization 
(described in detail in Fig. S2 and in methods), we found that rs3480 satisfied our criteria. FNDC5 
rs3480 was confirmed to be in Hardy–Weinberg equilibrium and showed a MAF of 0.41; 0.403, 
0.41 and 0.404 in Australian, Italian and Spanish samples, respectively, similar to that observed in 
other European populations (MAF = 0.41), http://browser.1000genomes.org). No differences in 
clinical, anthropometric and biochemical indices including aminotransferases were found between 
the FNDC5 rs3480 genotypes (Table S3). 
Fixed-effects meta-analysis of the association of rs3480 with steatosis (S2-S3) was significant (OR 
1.20; 95% CI 1.01–1.3; meta-p = 0.0001; Fig. 1A). In multivariate logistic regression analysis 
incorporating age, gender, body mass index (BMI), type 2 diabetes mellitus, recruiting center and 
PNPLA3 rs738409 and TM6SF2 rs58542926 genotype, the FNDC5 rs3480 (G) allele was 
associated with an increased risk of steatosis (S2-S3) (OR 1.29; 95% CI 1.08–1.55; p = 0.004) 
(Table S4). 
 
PNPLA3, TM6SF2 and FNDC5 polymorphisms have an additive effect 
We next examined the proportion of attributable risk conferred by the FNDC5, PNPLA3, and 
TM6SF2 genetic variants. As expected, the PNPLA3 I148M variant had the largest impact on 
steatosis (S2-S3); the estimated population-attributable risk (PAR) was 25.1%. Of interest, the 
FNDC5 rs3480 variant had a greater PAR compared to the E167K TM6SF2 variant (10.6% vs. 
6.7%, respectively). 
We then examined the interaction between the 3 variants but did not observe an impact on hepatic 
steatosis (p >0.05). Instead, the 3 variants appeared to have an additive impact with a stepwise 
increase in odds ratio for steatosis (S2-S3) for each additional risk allele (p <0.0001 for trend) (Fig. 
1). In total, FNDC5 rs3480 is a novel risk variant for steatosis, independent, but additive to the 
known risk variants, PNPLA3 and TM6SF2. 
 
FNDC5 rs3480 and the severity of hepatic inflammation and fibrosis 
We tested the association of FNDC5 rs3480 with the severity of lobular inflammation and 
ballooning. FNDC5 rs3480 was not associated with more severe lobular inflammation (A2-A3) (OR 
1.3; 95% CI 0.9–1.87; p = 0.1) and remained the same after adjustment for age, sex, BMI, diabetes, 
and severity of steatosis (p = 0.2). Similarly, no association with fibrosis (F2-F4) was observed 
(OR 1.05; 95% CI 0.74–1.47; p = 0.7), which remained the same after adjustment for the variables 
previously mentioned (p = 0.79). 
Impact of SNP at rs3480 on the 3′UTR of FNDC5 
To investigate the mechanisms for the genetic association, we evaluated the influence of the 3′UTR 
SNP rs3480 on the post-transcriptional regulation and stability of FNDC5 mRNA. To examine 
whether mRNA folding of FNDC5 could be altered by rs3480, bioinformatic analysis using the 
RNAfold web server was used. This demonstrated that rs3480 SNPs altered mRNA structure, 
suggesting that it may affect the stability of FNDC5 mRNA, with a marginal variation in the MFE, 
from ΔG =  −1102.20 to −1102.10 kcal mol−1 (Fig. S2). 
To validate these findings, we generated full-length 3′UTRs of FNDC5 containing either the G or 
the A allele and cloned them into the pmirGLO vector (Fig. 2A), then transfected human hepatoma 
(Huh-7) cells with the constructs and measured luciferase activity. The FNDC5-G 3′ UTR conferred 
significantly lower luciferase activity compared to the FNDC5-A 3′UTR (Fig. S3). We next 
assessed the effect of rs3480 on mRNA stability. Analysis of the luciferase–encoding mRNA that 
remained in Huh-7 cells after treatment with actinomycin D revealed that mRNA bearing the 
FNDC5-G 3′UTR decayed significantly faster than that bearing the FNDC5-A 3′UTR (Fig. 2B). 
This implies that rs3480 alleles affect the stability of the mRNA transcript. 
Next, we performed allele-specific expression analysis using pyrosequencing of gDNA (blood) and 
cDNA from 10 human liver samples from rs3480 heterozygous individuals. As demonstrated in Fig. 
S4, modest but significant allelic differences in gene expression were observed, with lower 
expression in the G allele (p = 0.003, nonparametric Wilcoxon's paired test). Together these data 
demonstrated that rs3480 influences the stability and expression of FNDC5. Regulation of FNDC5 by miRNA 
We investigated whether the rs3480 SNP could influence recruitment of miRNAs to the 3′UTR of 
FNDC5. Bioinformatics analysis of the 3′UTR sequence around the site of rs3480 identified 
potential binding sites for miR-135a-5P and miR-135b-5P (Fig. 2C). To investigate the preferential 
binding of the miRNAs to the rs3480 alleles, we co-transfected Huh-7 cells with miR-135a-5P and 
miR-135-5P and negative control mimics with luciferase reporter constructs containing FNDC-A or 
FNDC5-G. The luciferase assay shows that miR-135a-5p binds to both A and G alleles, but 
preferentially to the G allele, demonstrated by significantly lower luciferase activity between G+ 
miR-135a-5p compared to A+ miR-135a-5p (Fig. 2D). Notably, the difference between alleles was 
blunted in the presence of the miR-135a-5P inhibitor (Fig. 2E), suggesting the specificity of 
decreased luciferase activity by miR-135a-5P. In contrast, miR-135b-5P binds to both alleles with 
no preferential binding (Fig. S5). Gene set enrichment analysis 
We then undertook pathway analysis of the common predicted targets of miR-135a-5P using KEGG 
pathway mapping. Collectively miR-135a-5P targets mapped onto different pathways (Fig. 2F and 
Table S5). Notably, they included overrepresentation of insulin signaling and type 2 diabetes 
pathways. Hepatic miRNA and FNDC5 levels in NAFLD 
We next interrogated hepatic levels of miR-135a-5P, miR-135b-5P and FNDC5 in liver from 
patients with NAFLD and controls by ddPCR. Compared to controls, patients with NAFLD had 
significantly higher levels of miR-135a-5P but not miR-135b (p <0.05, Fig. 3A and Fig. S6). 
FNDC5 levels tended to be lower in NAFLD, but not significantly (Fig. 3B). A statistically 
significant (r2 = 0.80 p ≤0.002) positive correlation was observed between miR-135a-5P and 
FNDC5 in liver from normal control individuals, while they were negatively correlated in NAFLD 
(r2 = −0.36) (Fig. S7). There was no difference in hepatic miR-135a and miR-135b levels according 
to rs3480 genotype (data not shown). 
 
 
Fig. 3. Absolute quantification of hepatic miR-135a-5p levels and FNDC5 levels. (A) miR-135a-5p levels 
are upregulated in NAFLD compared to controls in liver samples. (B) FNDC5 levels are downregulated in 
the livers of patients with NAFLD compared to controls (n = 10 controls, n = 10 NAFLD). *p <0.05, 
**p <0.01, ***p <0.001 by Mann-Whitney U test. Boxplots are median, minimum and maximum. 
 
Elevated circulating irisin is associated with reduced steatosis and a favorable metabolic profile 
Finally, we examined which clinical parameters were associated with serum irisin level in a sub-
cohort of patients with NAFLD (n = 152) having available serum. Irisin levels correlated positively 
with high-density lipoprotein cholesterol levels (p <0.001), and negatively with HOMA-IR 
(p = 0.04). No correlations were observed with other clinical parameters (Table S6). Median irisin 
levels were higher in patients less than 40 years old compared to those ≥40 years old (p <0.01) (Fig. 
4A) and in individuals with HOMA-IR <3 compared to those with HOMA-IR ≥3 (p <0.001) (Fig. 
4B). Irisin serum levels were similar between females and males (p = 0.5). Finally, serum irisin 
levels (Fig. 4C) were lower in those with greater steatosis compared to those with mild steatosis 
(p <0.03), but did not differ by other histological features. Patients with the GG genotype had a 
trend towards lower median irisin levels compared with individuals carrying at least one A allele, 
though it was not significant (p = 0.07, Fig. S7). No difference in irisin level according to PNPLA3 
or TM6SF2 genotypes was observed. Collectively, elevated serum irisin levels are associated with 
reduced steatosis and an improved metabolic profile. 
 
 
Fig. 4. Serum irisin levels. Serum irisin levels by (A) HOMA-IR, (B) age and (C) steatosis in a sub-cohort of 
152 patients with NAFLD. Boxplots are median, minimum and maximum. Statistical significance was 
analyzed by the Mann-Whitney U test. The number of samples tested in each group is shown. 
 
Discussion 
In this study, we demonstrate that FNDC5 rs3480 is a novel additional and possibly hitherto 
overlooked genetic variant affecting the risk of hepatic steatosis in NAFLD. The influence of the 
risk genotype was independent of, but additive to PNPLA3 and TM6SF2 in Caucasian patients. We 
show a 1.4- to 6.8-fold increase in hepatic steatosis risk based on the cumulative association of the 3 
variants among individuals who had at least one copy of the risk allele at each of the 3 regions, 
compared with individuals without any risk alleles. The G allele associated with greater FNDC5 
mRNA degradation compared to A allele, had a modest but significant effect on liver FNDC5 
allele-specific expression and also created a binding site for miR-135a-5P. Compared with controls, 
patients with NAFLD had significantly higher levels of hepatic miR-135a-5p and lower FNDC5. 
Concomitantly, this miRNA can regulate several pathways linked to liver disease including those 
for insulin signaling and type 2 diabetes. Lastly, elevated serum irisin levels were associated with 
reduced steatosis and with improved indices of the circulating metabolic profile. Collectively, these 
data suggest that miRNA binding to an SNP in the 3′UTR, impairs FNDC5 expression and thereby 
increases the severity of hepatic steatosis (Fig. 5). 
 
 
Fig. 5. Proposed model for the regulation of FNDC5 and hepatic steatosis. miR-135a-5p binds 
preferentially to the G allele of rs3480 in the 3′UTR of the FNDC5 gene. Consequently, miRNA mediated 
decay of FNDC5 is enhanced and this results in less FNDC5 mRNA. As FNDC5 has favorable metabolic 
impacts, this results in greater hepatic steatosis. 
 
While carriage of the FNDC5 rs3480 (G) minor allele was associated with an increased risk of 
steatosis, it did not impact other histologic features. The influence on steatosis was also independent 
of known steatosis risk confounders including age, gender, BMI, type 2 diabetes mellitus and 
recruitment center. Since no interaction was observed between FNDC5 rs3480, PNPLA3 rs738409 
and TM6SF2 rs58542926 genotypes, our data suggests that the 3 genes regulate different pathways 
in steatosis pathogenesis. 
Serum irisin levels were reduced in individuals with greater hepatic steatosis (S2-S3). Both in a 
study of 296 obese Chinese adults in whom hepatic triglyceride content was determined by 1H MRS 
spectroscopy21 and another of 84 Koreans with NAFLD in whom steatosis was measured by 
abdominal ultrasonography,19 irisin levels declined with increased liver fat. However, in another 
small study (n = 31) of patients with biopsy-proven NAFLD, no difference in serum irisin according 
to steatosis grade was observed.20 These studies used the same ELISA kit and thus differences are 
likely due to sample size considerations. While there has been skepticism on the quality of 
commercial ELISAs to quantify irisin, in the present work it was measured using the recently 
released Phoenix Pharmaceuticals (EK-067-29) kit that has been validated by comparison with data 
from Western blot and MALDI-TOF mass spectrometry.27 
The mechanisms for the protective effects of irisin on hepatic steatosis in NAFLD are not clear, but 
evidence suggests both direct and indirect beneficial effects. In humans, FNDC5 is expressed in 
skeletal muscle and adipose tissues serving as both a myokine and adipokine, though the principle 
source appears to be muscle.33 In the liver, hepatocyte-released irisin functions as a 
paracrine/autocrine hormone.34 It has been reported that adipose tissue FNDC5 mRNA and 
circulating irisin levels negatively correlate with hyperglycemia, elevated triglycerides, visceral 
adiposity and extramyocellular lipid deposition, features that are concordant with the metabolic 
abnormalities observed in NAFLD.35 Moreover, treating muscle cells in vitro with palmitate and 
glucose lowered FNDC5 mRNA suggesting peripheral effects on metabolic and glucose 
homeostasis.35 This data is supported by animal studies that FNDC5 improves hepatic steatosis, 
protects mice against genetic- and diet-induced obesity, and improves hepatic and peripheral insulin 
resistance via regulating AMPK signaling in myocytes and hepatocytes.[34], [36], [37], [38] 
miRNAs are small non-coding RNA transcripts of ∼22 nucleotides that regulate gene expression at 
the post-transcriptional level.39 They do so by targeting sites of complementarity in the 3′UTR of 
mRNAs, thereby mediating mRNA decay or translational repression. miRNAs can repress multiple 
targets within the same pathway resulting in amplification of their biological effects. SNPs can 
create, destroy or modify sites for miRNA binding. Our results reveal that rs3480 with an A-to-G 
substitution in the 3′UTR of FNDC5 results in decreased expression of FNDC5 through two post-
transcriptional mechanisms. Firstly, FNDC5-G suffered more degradation than did FNDC5-A; 
secondly, it also differentially bound mir-135a-5P. Hepatic levels of mir-135a-5P and FNDC5 as 
measured by ddPCR were upregulated and downregulated, respectively, in patients with NAFLD 
compared with controls. Not surprisingly, a positive correlation was present between mir-135a-5P 
and FNDC5 in normal individuals, while this correlation was reversed in NAFLD. This suggests 
that miRNA modulation of FNDC5 might be a form of “compensatory adaptation“ in normal liver, 
whereby the miRNAs do not downregulate the expression of FNDC5 and might indicate a signal for 
transcript downregulation. When fatty liver develops, the correlation becomes negative as adaptive 
mechanisms fail. mir-135a-5P is modulated more than FNDC5 in NAFLD, suggesting that 
induction of mir-135a-5P might be an early event in NAFLD development. Consistently, miR-135a 
levels were elevated in serum, plasma, renal and skeletal muscle in patients with diabetes compared 
to controls.[40], [41], [42] Notably, our pathway analysis also suggested that miR-135a maps to 
different pathways, including an overrepresentation of insulin signaling and type 2 diabetes 
pathways. In this regard, mir-135a has been shown to inhibit insulin signaling and glucose uptake 
by targeting insulin receptor substrate 2 (IRS2). Of relevance, we demonstrated that serum irisin 
level was negatively correlated with HOMA-IR. 
We found no association between FNDC5 rs3480 genotype or serum irisin levels with histological 
disease activity or fibrosis, or with liver tests as indices of liver injury. According to our data, 
genotypic variation at rs3480 has a modest effect size on steatosis and thus is likely insufficient to 
influence the transition to steatohepatitis and fibrosis. Our data however do not exclude the 
possibility of effects on inflammation and fibrosis in larger cohorts powered to detect such effects. 
This is relevant, as we have shown that serum irisin levels demonstrate an inverse correlation with 
measures of insulin resistance and dyslipidemia that are associated with inflammation and 
fibrosis.[12], [43] However, the alternate possibility is that irisin disentangles steatosis from 
fibrosis. In this context, we have previously shown that serum leptin correlates with steatosis but 
not fibrosis in NAFLD,14 suggesting both shared and differential pathways between susceptibility to 
steatosis and risk of disease progression. 
A recent smaller study (n = 593) reported that the rs3480 (G) allele was associated with the severity 
of hepatic steatosis only in univariate analysis, consistent with our finding, while the association 
was lost after multiple logistic regression.44 Surprisingly, in that study, the same allele was 
associated with less severe hepatic fibrosis. The reasons for this discrepancy are unclear. 
In conclusion, in this study we characterized a functional FNDC5 variant as an additional risk 
variant associated with hepatic steatosis independently of PNPLA3 and TM6SF2. This 
polymorphism influenced transcript stability, as well as the binding of miRNAs, suggesting a model 
whereby rs3480 modulates steatosis by regulating FNDC5 expression. 
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